Watchlist · 70/100Oct 23, 10:44 AM EDT
Alnylam's brezosiran cuts mutant huntingtin by up to 83% in early Huntington's trial
ALNY
Alnylam reported phase 1b data showing its Huntington's disease candidate brezosiran reduced cerebrospinal fluid mutant huntingtin by a mean of 60-64% at three months, with a maximum individual reduction of 83%. The early-stage results suggest the RNAi therapy…
- ▹Promising Phase 1b data with 60-64% mean mHTT reduction and 83% max, validating Alnylam's RNAi platform for CNS delivery.
- ▹Early-stage asset with no regulatory designations yet; commercial potential years away, but platform strength and pipeline depth support a Watchlist rating.
Watchlist · 67/100Oct 22, 5:03 PM EDT
BioNTech and Gilead Partner to Test Pumitamig with Trodelvy in Triple-Negative Breast Cancer
BNTXGILD
BioNTech has teamed up with Gilead to evaluate its drug pumitamig in combination with Gilead's Trodelvy as a first-line treatment for PD-L1 low or negative triple-negative breast cancer. The collaboration aims to explore a new combination regimen for this aggr…
- ▹BioNTech-Gilead combo trial for pumitamig plus Trodelvy in TNBC; early-stage but validates platform and adds a differentiated ADC combination asset.
- ▹Regulatory and commercial scores capped by trial-stage status; narrative held back by single-asset risk and no near-term catalysts.
Neutral · 57/100Oct 22, 4:45 PM EDT
Gilead Bolsters Immunology Pipeline with $1.3B Acquisition of Oral IL-23R Inhibitor from PepStar
GILD
Gilead Sciences acquired an oral IL-23R inhibitor program from private biotech PepStar Therapeutics for approximately $1.3 billion, including lead candidate HCXT-2001, currently in Phase 1 trials. The deal adds a promising asset targeting a clinically validate…
- ▹Phase 1 asset with validated target but no clinical data yet; regulatory path uncertain.
- ▹Gilead adds oral IL-23R to pipeline, but early-stage and single-asset deal limits near-term impact.
High Risk · 48/100Oct 22, 4:17 PM EDT
Moderna Shares Plunge 17% on Leaked Cancer Vaccine Data
MRNA
Moderna's stock fell 17% to $203.20 on Thursday after leaked clinical data from its personalized cancer vaccine program sparked a sharp selloff. The leak raised concerns about the vaccine's efficacy, prompting investors to reassess the company's oncology pipel…
- ▹Leaked cancer vaccine data triggered a 17% selloff, signaling negative data/controversy and eroding confidence in the personalized cancer vaccine program
- ▹Moderna is a platform company with commercialized products, but the leak introduces data-integrity and clinical-risk overhang that caps the narrative score
High Risk · 45/100Oct 23, 2:26 AM EDT
Zai Lab Secures $250M Through Private Placement of ADSs
ZLAB
Zai Lab (ZLAB) has agreed to sell 11.34 million American Depositary Shares (ADSs) in a private placement at $22.04 per ADS, raising approximately $250 million in gross proceeds before fees. The PIPE financing provides the company with significant capital, whic…
- ▹PIPE financing dilutes existing shareholders and signals potential cash runway concerns, a negative narrative event.
- ▹No new regulatory, clinical, or commercial catalysts; Zai Lab remains a China-based biotech with limited US/EU manufacturing footprint.
High Risk · 30/100Oct 22, 5:22 PM EDT
Enlivex to Execute 1-for-16 Reverse Stock Split on October 27
ENLV
Enlivex Therapeutics (ENLV) will implement a 1-for-16 reverse stock split effective October 27, 2026, reducing its outstanding shares from approximately 24.51 million to 1.53 million. The move is likely aimed at maintaining Nasdaq listing compliance and may si…
- ▹Reverse split is a distress signal, likely to maintain Nasdaq listing and avoid delisting; no operational or clinical catalyst.
- ▹Single-asset micro-cap with no commercialized product, no recent FDA progress, and high dilution risk; narrative heavily penalized.
High Risk · 20/100Oct 23, 2:21 AM EDT
Lunai Bioworks Faces Nasdaq Delisting Over Equity Shortfall
LNAI
Lunai Bioworks received a Nasdaq delisting determination after failing to meet the $2.5 million minimum stockholders' equity requirement, reporting a $9.02 million deficit as of June 30, 2026. Trading is expected to be suspended on October 30, 2026, with the d…
- ▹Nasdaq delisting determination and $9.02M stockholders' deficit signal severe financial distress and imminent trading suspension
- ▹No regulatory, clinical, or commercial catalysts; pure governance/listing failure with no investable thesis